The Center for Liver Disease includes a research program that is fully committed to advancing patient care, teaching and research. The Center performs state-of-the-art clinical trials focusing on the treatment of liver disease in order to bring new treatments patients and their families. The general focus of these trials is to gain a better understanding of the nature and behavior of these diseases in an effort to develop more effective treatments.
The Center is currently involved in clinical trials for Hepatitis C, Hepatitis B and Nonalcoholic Steatohepatitis (NASH), a common, often silent liver disease. It resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. The major feature in NASH is fat in the liver, along with inflammation and damage.
With specific reference to Hepatitis C, the Center participates in clinical trials exploring novel therapies for the virus.
The Center is currently recruiting patients for clinical trials in the field of:
- Examination of the Hepatitis C virus general nature/behavior, with particular focus on how the virus replicates
- Examination/evaluation of how currently utilized medications work to combat the virus
The Center is committed to the continued education of its physicians and staff to ensure it remains a forerunner in the area of liver disease research and treatment. This commitment includes fostering inter-institutional collaboration with Hepatitis C virus experts outside of the Center, allowing us to continue to deliver the latest developments in research and treatment to the public. To learn more about our specific trials, visit the Feinstein Institute. Back to Top